Alogliptin clinical trials
Also written SYR-322, Nesina and SYR110322.
How each study uses alogliptin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 25 Jan 2013 · NESINA · NDA 022271 (FDA, Drugs@FDA)
- European Union
- 18 Sept 2013 · Vipidia · EMEA/H/C/002182 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
44 studies that test it; most in 2006 (8)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 4 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 6
Takeda (35) · Kun-Ho Yoon (2) · Celltrion Pharm, Inc. (1) · Sanofi (1) · AstraZeneca (1) · Fourth People's Hospital of Shenyang (1) · Seoul National University Hospital (1) · University of Catanzaro (1)
Often tested with
Tested in the same studies.
Pioglitazone (6) · Metformin (6) · Trelagliptin (2) · Voglibose (2) · Glimepiride (2) · Roflumilast (1) · Insulin (1)
Related medicines
As reviewed, each with the page that says it.
- One of DPP-4 inhibitors source
- One of Hypoglycemic Agents source
Studies
Open first, then newest update. How each study uses alogliptin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 44
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin TherapyCompletedPhase 4Celltrion Pharm, Inc.NCT03499704Written as Pioglitazone + Alogliptin
- Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes MellitusCompletedPhase 4TakedaNCT03231709Written as Alogliptin
- An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes MellitusCompletedPhase 4TakedaNCT02771093Written as Alogliptin
- Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male SubjectsCompletedPhase 3TakedaNCT02276274Written as SYR-322-MET
- Phase 3 Alogliptin Pediatric StudyCompletedPhase 3TakedaNCT02856113Written as Alogliptin Benzoate
- Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug NaiveCompletedPhase 4SanofiNCT03794336Written as Alogliptin
- Glimepiride, Alogliptin and Alogliptin+Pioglitazone CombinationStatus unknownPhase 4Seoul National University HospitalNCT04470310Written as Alogliptin 25Mg Tab
- Anti-inflammatory Status in DM2 Treated PatientsStatus unknownPhase 4University of CatanzaroNCT04392557Written as Metformin / alogliptin Oral Product
- An Extension Study of PEAK TrialTerminatedPhase 4Kun-Ho YoonNCT02763007Written as alogliptin+pioglitazone
- The Practical Evidence of Antidiabetic Combination Therapy in KoreaCompletedPhase 4Kun-Ho YoonNCT02231021Written as alogliptin
- Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes MellitusWithdrawnPhase 4TakedaNCT03042325Written as Alogliptin
- Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 DiabetesCompletedPhase 1AstraZenecaNCT01664624Written as Alogliptin
- Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 DiabetesCompletedPhase 3TakedaNCT01890122Written as Alogliptin
- The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin MonotherapyCompletedNot applicableFourth People's Hospital of ShenyangNCT02798172Written as Alogliptin and Metformin
- Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes MellitusCompletedPhase 1TakedaNCT00957268Written as Alogliptin
- Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary SyndromeCompletedPhase 3TakedaNCT00968708Written as Alogliptin
- Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 DiabetesCompletedPhase 3TakedaNCT01456130Written as Alogliptin
- Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes MellitusCompletedPhase 3TakedaNCT00856284Written as Alogliptin
- Study of Combination Therapy With SYR-322CompletedPhase 3TakedaNCT01521962Written as Alogliptin
- Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.CompletedPhase 3TakedaNCT00655863Written as Alogliptin and Pioglitazone
See all 44 studies that test alogliptin →
Given beside what is tested · 4 — alogliptin is usual care or a partner of the new treatment
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminRecruitingPhase 3CelltrionNCT07093476Written as Alogliptin
- Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise TherapyCompletedPhase 3TakedaNCT02068443Written as Alogliptin
- A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian ParticipantsCompletedPhase 1TakedaNCT03501277Written as Alogliptin
- Phase 1 Bioavailability Study of SYR-322METCompletedPhase 1TakedaNCT02508168Written as Alogliptin
As the comparator · 5 — what is tested is compared with alogliptin
- Double-blind Comparative Study of SYR-472CompletedPhase 3TakedaNCT01632007Written as Alogliptin 25 mg
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedPhase 3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT05782192Written as Alogliptin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy VolunteersCompletedPhase 1CelltrionNCT05363592Written as Alogliptin Benzoate 12.5 mg
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy VolunteersCompletedPhase 1CelltrionNCT05363384Written as Alogliptin Benzoate 25 mg
- Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes MellitusTerminatedPhase 2TakedaNCT00763347Written as Alogliptin
Codes
What other systems call alogliptin · ClinicalTrials.gg INT005111
- MeSH (NLM) C520853alogliptinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) JHC049LO86ALOGLIPTINConfirmed FDA, NLM, Wikidata
- RxNorm 1368001Confirmed FDA, Wikidata
- Wikidata Q4734170alogliptinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76906AlogliptinOne source FDA
- DrugBank DB06203One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520853 | alogliptin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | JHC049LO86 | ALOGLIPTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1368001 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4734170 | alogliptin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76906 | Alogliptin | One source FDA |
| DrugBank | DB06203 | — | One source Wikidata |
Also registered as alogliptin benzoate (UNII EEN99869SC · RxNorm 1368000).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.